// App-Quantinova.ai

: Melatonin ameliorates glucocorticoid-induced invasiveness and circadian rhythm disruption in human endometrial adenocarcinoma cells

Researchers

Presenter

  • Angeliki Karapanagioti

Principal Investigators

  • Narjes Nasiri-Ansari

  • Ioannis Kyrou

  • Despoina Mavrogianni

  • Peter Drakakis

  • gregory kaltsas

  • Athanasios G. Papavassiliou

  • Harpal Randeva

  • Eva Kassi

Medical Centers

  • National and Kapodistrian University of Athens, Medical School, 4nd Department of Internal Medicine, Attikon Hospital, Athens, Greece

  • National & Kapodistrial University of Athens, Medical School, 2nd Department of Psychiatry, Athens, Greece

  • Aston University, Aston Medical Research Institute, Aston Medical School, College of Health and Life Sciences, Birmingham, United Kingdom

  • University Hospital Coventry & Warwickshire, Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism (WISDEM), Coventry, United Kingdom

  • Agricultural University of Athens, Department of Food Science and Human Nutrition, Athens, Greece

  • Coventry University, Centre for Sport, Exercise and Life Sciences, Research Institute for Health & Wellbeing, Coventry, United Kingdom

  • University of Warwick, Medical School, Coventry, United Kingdom

  • National and Kapodistrian University of Athens, Medical School, 1st Department of Obstetrics and Gynecology, Division of Human Reproduction, IVF Unit, Alexandra Hospital, Athens, Greece

Locations

  • Greece

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Endometrial Cancer

Biomarkers

  • Aryl hydrocarbon receptor nuclear translocator-like protein 1

  • CLOCK

Drug/Treatment

  • Glucocorticoid

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Melatonin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved